These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32042326)

  • 1. SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer.
    Chen J; Wu Z; Ding W; Xiao C; Zhang Y; Gao S; Gao Y; Cai W
    Theranostics; 2020; 10(4):1619-1632. PubMed ID: 32042326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Codelivery of miR-4638-5p and Docetaxel Based on Redox-Sensitive Polypeptide Micelles as an Improved Strategy for the Treatment of Castration-Resistant Prostate Cancer.
    Jiang W; Gao Y; Wang Z; Gong C; Hu C; Ding X; Qiang L; Gao S; Ren F
    Mol Pharm; 2019 Jan; 16(1):437-447. PubMed ID: 30452268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.
    Festuccia C; Mancini A; Gravina GL; Colapietro A; Vetuschi A; Pompili S; Ventura L; Delle Monache S; Iorio R; Del Fattore A; Fogler W; Magnani J
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
    Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
    Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
    [No Abstract]   [Full Text] [Related]  

  • 5. CRPC Membrane-Camouflaged, Biomimetic Nanosystem for Overcoming Castration-Resistant Prostate Cancer by Cellular Vehicle-Aided Tumor Targeting.
    Lu K; Li Z; Hu Q; Sun J; Chen M
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
    Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
    Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mifepristone Has Limited Activity to Enhance the
    Yang Y; Li X; Mamouni K; Kucuk O; Wu D
    Anticancer Res; 2017 Nov; 37(11):6235-6243. PubMed ID: 29061806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.
    Hoang B; Ernsting MJ; Murakami M; Undzys E; Li SD
    Int J Pharm; 2014 Aug; 471(1-2):224-33. PubMed ID: 24853460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
    Babasaki T; Sentani K; Sekino Y; Kobayashi G; Thang Pham Q; Katsuya N; Akabane S; Taniyama D; Hayashi T; Shiota M; Oue N; Teishima J; Matsubara A; Yasui W
    Cancer Med; 2021 Aug; 10(16):5574-5588. PubMed ID: 34240817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent advances in treatment of patients with castration-resistant prostate cancer after docetaxel failure].
    Chen BD; Yu SC; Li GH
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jan; 43(1):115-8. PubMed ID: 24616470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A; Kim SH; Hwang C
    Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
    Hoang B; Ernsting MJ; Tang WS; Bteich J; Undzys E; Kiyota T; Li SD
    Cancer Lett; 2017 Dec; 410():169-179. PubMed ID: 28965854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-interactive mPEG-
    Gong F; Wang R; Zhu Z; Duan J; Teng X; Cui ZK
    Drug Deliv; 2020 Dec; 27(1):238-247. PubMed ID: 32003299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of PSMA-targeted and core-crosslinked glycol chitosan micelles for docetaxel delivery in prostate cancer therapy.
    Feng X; Zhou Y; Xie X; Li M; Huang H; Wang L; Xu X; Yu J
    Mater Sci Eng C Mater Biol Appl; 2019 Mar; 96():436-445. PubMed ID: 30606553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.
    Mitra Ghosh T; Mazumder S; Davis J; Yadav J; Akinpelu A; Alnaim A; Kumar H; Waliagha R; Church Bird AE; Rais-Bahrami S; Bird RC; Mistriotis P; Mishra A; Yates CC; Mitra AK; Arnold RD
    Cancer Res Commun; 2023 Jul; 3(7):1286-1311. PubMed ID: 37476073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
    Szarvas T; Sevcenco S; Módos O; Keresztes D; Nyirády P; Kubik A; Romics M; Kovalszky I; Reis H; Hadaschik B; Shariat SF; Kramer G
    Urol Oncol; 2018 Jun; 36(6):312.e9-312.e15. PubMed ID: 29628317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
    Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF
    Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment.
    Zhang Y; Duan H; Zhao H; Qi L; Liu Y; Zhang Z; Liu C; Chen L; Jin M; Guan Y; Gao Z; Huang W
    Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.